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Necrotizing enterocolitis (NEC) is one of the most common
gastrointestinal emergencies in preterm infants, with sig-
nificant mortality and morbidity rates.1 The etiology and
pathogenesis of NEC are incompletely understood with
most researchers agreeing that it is a multifactorial dis-
ease, which is often associated with enteral feeding,
ischemia, and infectious causes.1 Prematurity and low
birthweight are the only determinants that are consistently
found to be associated with increased frequency of the
occurrence of NEC.2
In an experimental study with porcines3 and in a double-
blind trial with premature infants,4 it was found that
reduced stomach acid levels were associated with higher
levels of Gram-negative bacteria and a higher likelihood of
occurrence of NEC. Recently, Guillet et al5 and Terrin et al6
found that histamine-2 receptor (H2) blocker therapy was
associated with an increased incidence of NEC.* Corresponding author. Center for Health Services Management
and Evaluation, University of Athens, Greece.
E-mail address: pegalan@nurs.uoa.gr (P. Galanis).
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http://dx.doi.org/10.1016/j.pedneo.2013.01.011The purpose of our study was to determine the incidence
of NEC and the relationship between H2-blocker therapy
and this disease in preterm infants.
2. Methods
The study population consisted of 232 infants with gesta-
tional age <37 weeks admitted to the NICU of a private
children’s hospital in Athens (Greece) between January
2007 and December 2009.
A case-control study was conducted and each case of
NEC was matched to one control on the basis of gesta-
tional age (2 weeks), birthweight (250 g), and year of
birth. These matching variables were selected to control
for any change in practice from one year to the next and
to ensure that the groups were similar as predicted by
gestational age and birthweight. Considering that death is
a competing risk for NEC, matched controls were selected
from among infants who survived until the chronological
age (days after birth) at which the associated case
developed NEC. NEC cases that took H2-blockers at least 1
day before NEC diagnosis and continuously took H2-
blockers until NEC diagnosis were considered as exposed;ed by Elsevier Taiwan LLC. All rights reserved.
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over, control infants that took H2-blockers at least 1 day
prior to the chronological age at which the matched case
was diagnosed were considered as exposed; otherwise,
they were considered as non-exposed. Diagnosis of NEC
was defined according to the Bell staging criteria.7
During the study period, the only H2-blocker that was
administrated in the Neonatal Intensive Care Unit (NICU) of
the hospital was ranitidine. Study data were collected from
infant’s individual medical records. Infants’ demographic,
clinical, and enteral feeding data, and maternal data were
collected.
The study protocol was approved by the ethical board of
the Faculty of Nursing of the University of Athens and the
institutional review board of the private children’s hospital.
All other regulations specific to medical record review
required by hospital policy were strictly adhered to by the
investigators.
Conditional logistic regression analysis was used
because the data were matched. Multivariate logistic
regression model was applied to assess the net effect of
H2-blocker treatment on NEC adjusted for potential con-
founders. A two-sided p < 0.05 was considered statistically
significant.
3. Results
From January 1, 2007 to December 31, 2009 a total of 116
infants with gestational age <37 weeks had a diagnosis of
NEC. During the study period, 5544 infants with gestational
age <37 weeks were admitted to the hospital’s NICU and
survived to at least 24 hours. The average annual incidence
of NEC was 2.1% [116 of 5544; 95% confidence interval (CI):
1.8e2.5].
During the study period, 20 (17.2%) NEC cases took
H2-blockers, whereas only 5 (4.3) control infants took
H2-blockers. After adjustment for potential confounders,
H2-blocker treatment was significantly associated with an
increased incidence of NEC [adjusted odds ratio (OR): 3.71;
95% CI: 0.98e14.03; pZ 0.05]. On multivariate conditional
logistic regression analysis, the only variable (other than
H2-blocker treatment) that independently associated withan increased incidence of NEC was infections (adjusted OR:
2.67; 95% CI: 1.26e5.65; p Z 0.010).
4. Discussion
We found that H2-blocker therapy was significantly asso-
ciated with an increased incidence of NEC in preterm in-
fants, taking into consideration a great number of potential
confounders including infants’ demographic, clinical, and
enteral feeding data, and maternal data. This finding is
consistent with the results of a prospective, double-blind
trial,4 a cohort study,6 and a case-control study.5 A proper
utilization of H2-blocker treatment in preterm infants is
imperative in order to decrease the incidence of NEC. This
should be the practice until evidence from randomized
controlled trials comes to light. Also, more investigations in
basic and clinical research are needed in order to improve
our knowledge of factors contributing to the risk of NEC and
possible preventive measures.
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